Comparison
Dulaglutide vs. Selank
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
923950-08-7
129954-34-3
Molecular weight
59670 g/mol
751.85 g/mol
Half-life
110 h
0.3 h
Sequence
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcThr-Lys-Pro-Arg-Pro-Gly-ProMechanism of action
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
4
of which in humans
5
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
2
1